Global metabolomic profiling of uterine leiomyomas
Background: Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers: MED12 mutations, HMGA2 upregulation, or inactivation of FH . The aim of this study was to identify metabolites and metabolic pathways that are dysregulated in different subtypes o...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2017-12, Vol.117 (12), p.1855-1864 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers:
MED12
mutations,
HMGA2
upregulation, or inactivation of
FH
. The aim of this study was to identify metabolites and metabolic pathways that are dysregulated in different subtypes of leiomyomas.
Methods:
We performed global metabolomic profiling of 25 uterine leiomyomas and 17 corresponding myometrium specimens using liquid chromatography–tandem mass spectroscopy.
Results:
A total of 641 metabolites were detected. All leiomyomas displayed reduced homocarnosine and haeme metabolite levels. We identified a clearly distinct metabolomic profile for leiomyomas of the
FH
subtype, characterised by metabolic alterations in the tricarboxylic acid cycle and pentose phosphate pathways, and increased levels of multiple lipids and amino acids. Several metabolites were uniquely elevated in leiomyomas of the
FH
subtype, including N6-succinyladenosine and argininosuccinate, serving as potential biomarkers for
FH
deficiency. In contrast, leiomyomas of the
MED12
subtype displayed reduced levels of vitamin A, multiple membrane lipids and amino acids, and dysregulation of vitamin C metabolism, a finding which was also compatible with gene expression data.
Conclusions:
The study reveals the metabolomic heterogeneity of leiomyomas and provides the requisite framework for strategies designed to target metabolic alterations promoting the growth of these prevalent tumours. |
---|---|
ISSN: | 0007-0920 1532-1827 1532-1827 |
DOI: | 10.1038/bjc.2017.361 |